Fitzpatrick Demands Answers on Libya

Calls on Administration to Provide Clarity Mar 25, 2011 Issues: Defense and National Security, Foreign Affairs LANGHORNE, Pa. – Congressman Mike Fitzpatrick today released the following statement on the ongoing United States military operations in Libya which commenced on March 19, 2011. “There are important questions that need to be answered by President Obama regarding…

Read More

Open Letter to Bucks Voters in Paper…

An Open Letter To Patrick Murphy And The Voters Of Bucks County By MARK AFFLECK, For The Philadelphia Bulletin Monday, July 12, 2010 Comments (1) According to the latest Rasmussen poll, 56 percent of likely voters rate Congressional performance as poor and only 12 percent of likely voters give Congress a rating of good or…

Read More

Dubious endorsement? Cuban leader endorses US health care reform, says it’s about time

ASSOCIATED PRESS: Dubious endorsement? Cuban leader endorses US health care reform, says it’s about time HAVANA (AP) — It perhaps was not the endorsement President Barack Obama and the Democrats in Congress were looking for. Cuban revolutionary leader Fidel Castro on Thursday declared passage of American health care reform “a miracle” and a major victory…

Read More

I repeat, can anyone explain this insanity?

Watch the latest news video at video.foxnews.com The abuse of political correctness? Symptoms of Corrupting Sickness It would be interesting to create a poll with these two photos and have people guess what’s happening. Most would never assume anything close to the real story. It appears to be a joyous homecoming, a reuniting of mother…

Read More

Coartem ® Earns First Priority Review Voucher

The first Priority Review Voucher issued under the Food and Drug Administration Amendments Act of 2007 (FDAAA) was awarded yesterday by the US Food and Drug Administration (FDA) to Novartis Pharmaceuticals Corp. in conjunction with the FDA’s approval for use in the United States of the antimalarial drug Coartem (artemether–lumefantrine) manufactured by Novartis. The priority…

Read More